Both AR gene amplification as well as somatically acquired AR enhancer events are extremely uncommon in hormone-naive prostate cancer, however, they are present in a large subset of CRPC cell lines and tissues [77], which indicates that treatment-induced selection pressure allows for this adaptive genomic response [73], 76, 74]. This evidence concerns the gene AR and prostate cancer.